Personalised melanoma vaccine succeeds

What's happened

Drugmakers Moderna and Merck have released Phase 3 results showing their personalised mRNA vaccine, intismeran, plus the immunotherapy pembrolizumab (Keytruda) has reduced the two‑year risk of melanoma recurrence or death by 42% and distant metastasis or death by 38% in a trial of about 1,137 patients. Data were released after partial results leaked and will be presented at ESMO.

What's behind the headline?

What the data mean

• The trial has shown a clear improvement in recurrence‑free survival: 82% of patients who received intismeran plus pembrolizumab were recurrence‑free at two years versus 70% for pembrolizumab plus placebo. The reported hazard ratio translates to a 42% reduction in the risk of recurrence or death and a 38% reduction for distant metastasis or death.

Why this matters now

• Personalised mRNA vaccines will move from experimental to realistic regulatory candidates. Moderna and Merck are engaging regulators and have said they will seek approval. The published Phase 3 result will accelerate investment and clinical programmes testing the same approach in kidney, bladder and lung cancers.

Limits and unanswered questions

• The trial has not yet shown an overall survival benefit. Overall survival remains the gold standard and regulators will scrutinise durability beyond two years. The vaccine did not help every patient; subgroup analyses and biomarkers will be needed to identify who benefits most.

Near‑term consequences

• Regulators will review the dossier and health systems will assess feasibility: each vaccine requires tumour sequencing and bespoke manufacture, which will raise costs and logistical hurdles. Payers and health services will therefore evaluate cost‑effectiveness before broad adoption.

Longer‑term forecast

• This result will force oncology centres and drug developers to scale personalised‑vaccine manufacturing and sequencing capacity. It will also concentrate research on combining personalised neoantigen vaccines with checkpoint inhibitors and on expanding to cancers less responsive to immunotherapy.

Bottom line

• The trial will change practice if regulators accept recurrence‑free survival as sufficient or if later data show overall survival gains. Either way, personalised cancer vaccines will become a major development axis in oncology over the next few years.

How we got here

Researchers have tested personalised cancer vaccines for decades. This Phase 3 trial enrolled roughly 1,137 patients with surgically removed, high‑risk melanoma. Participants all received pembrolizumab; two‑thirds also received the tailored intismeran vaccine made from each patients tumor mutations. The companies have accepted the data for New England Journal of Medicine publication and will pursue regulatory review.

Our analysis

The coverage overlaps on the core result but frames implications differently. CNBC quotes investigators calling the result an "important milestone" and highlights expert caution on durability: "this has the potential to be a major breakthrough" (Dr. Sekwon Jang) while noting investor scepticism after leaked data (CNBC, Oct. 23). The New York Times reported the 42% reduction and quoted Dr. Steven Rosenberg and others to place the result within decades of vaccine research; it emphasised that overall survival has not yet been shown and that broader application to other cancers is uncertain (Nina Agrawal, NYT, Oct. 23). The Guardian presented the trial as "the first individualised cancer vaccine to show positive results in a phase III clinical trial," quoted Prof Georgina Long calling it "a foundational shift," and noted the New England Journal of Medicine acceptance and the need for peer review (The Guardian, Oct. 23). BBC Business and AP described the trial design and the 82% versus 70% two‑year recurrence‑free figures and highlighted practical barriers: manufacturing, tumour sequencing and NHS cost concerns (BBC Business, Oct. 23; AP, Oct. 22). Ars Technica, Reuters and other outlets stressed that the companies released top‑line results after an embargo break and that regulators are being engaged; Ars noted the vaccine encodes up to 34 neoantigens per patient (Ars Technica, Oct. 22). Together, the sources show consensus on the magnitude of the two‑year benefit and agreement that overall survival and long‑term durability remain unresolved, while business coverage adds investor and regulatory reaction.

Go deeper

• How will regulators judge recurrence‑free survival versus overall survival for approval?
• Which patients are most likely to benefit from the personalised vaccine?
• How will health systems manage the cost and logistics of bespoke vaccine manufacture?

More on these topics

• melanoma - Malignant neoplasm originating from melanocytes

  Melanoma is a type of cancer, typically skin cancer; it develops from the melanin-producing cells known as melanocytes. It typically occurs in the skin, but may rarely occur in the mouth, intestines, or eye (uveal melanoma). In very rare cases melanoma can also happen in the lung, which is known as primary pulmonary melanoma and only happens in 0.01% of primary lung tumors. In females, melanomas most commonly occur on the legs; while in males, on the back. Melanoma is frequently referred to as malignant melanoma. However, the medical community stresses that there is no such thing as a 'benign melanoma' and recommends that the term 'malignant melanoma' should be avoided as it is redundant. About 30% of melanomas develop from moles. Changes in a mole that can indicate melanoma include increase—especially rapid increase—in size, irregular edges, change in color, itchiness, or skin breakdown. The primary cause of melanoma is ultraviolet light (UV) exposure in those with low levels of the skin pigment melanin. The UV light may be from the sun or other sources, such as tanning devices. Those with many moles, a history of affected family members, and poor immune function are at greater risk...

• Madrid - Capital of Spain

  Madrid is the capital and most populous city of Spain. The city has almost 3.3 million inhabitants and a metropolitan area population of approximately 6.5 million.

• European Society for Medical Oncology - Professional association

  The European Society for Medical Oncology is a professional organisation for medical oncology. With more than 50,000 members representing oncology professionals worldwide, ESMO was founded in 1975.

• Cancer vaccine - Vaccine that either treats existing cancer or prevents development of cancer

  A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient. The immune system normally destroys cancer cells in a process called immunosurveillance. However, cancers can adapt to evade the immune system. Tumors form when the immune system fails to destroy cancer cells and they are able to multiply. Some types of cancer, such as cervical cancer and liver cancer, are caused by viruses (oncoviruses). Traditional vaccines against those viruses, such as the HPV vaccine and the hepatitis B vaccine, prevent those types of cancer. Other cancers are to some extent caused by bacterial infections (e.g. stomach cancer and Helicobacter pylori). Traditional vaccines against cancer-causing bacteria (oncobacteria) are not further discussed in this article.

• Memorial Sloan Kettering Cancer Center - Cancer treatment and research institution in New York City, United States

  Memorial Sloan Kettering Cancer Center (MSK or MSKCC) is a cancer treatment and research institution in Manhattan in New York City. MSKCC is one of 72 National Cancer Institute–designated Comprehensive Cancer Centers. Its main campus is located at 1275 York Avenue between 67th and 68th Streets in Manhattan. It was formed in 1980 from the merger of the Memorial Hospital for the Treatment of Cancer and Allied Diseases, founded in 1884, and the adjacent Sloan-Kettering Institute for Cancer Research, founded in 1945. The two medical entities had formally coordinated their operations since 1960.